Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications
Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...
Le Lézard4h
VERZENIO's Market Potential Soars as Demand for CDK4/6 Inhibitors Grows | DelveInsight
DelveInsight's "VERZENIO Market Size, Forecast, and Market Insight Report" highlights the details around VERZENIO, which is a targeted treatment known as ...
Agilent’s PD-L1 IHC 28-8 pharmDx gets added indications under EU IVDR1 for NSLC
Technologies announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...
Business Wire3d
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications
PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the Agilent Autostainer Link 48 advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide ...
TMCnet13h
BostonGene Named a Fierce Life Sciences Innovation Awards Winner in the AI Innovation Category
BostonGene, a leading provider of artificial intelligence (AI)-driven molecular and immune profiling solutions, today announces it was named a Fierce Life Sciences Innovation Awards winner by Fierce ...
DelveInsight Business Research, LLP: VERZENIO's Market Potential Soars as Demand for CDK4/6 Inhibitors Grows | DelveInsight
As VERZENIO gains traction in early-stage treatments and broadens its approved uses, its revenue is expected to keep growing. While the global CDK4/6 inhibitor market remains highly competitive ...
Pharmabiz2d
Tethis collaborates with Sheba Medical Center to advance AI-powered liquid biopsy in rectal cancer
Tethis collaborates with Sheba Medical Center to advance AI-powered liquid biopsy in rectal cancer: Milan, Italy Tuesday, March 11, 2025, 13:00 Hrs [IST] Tethis S.p.A., a pioneer ...